Evidence map›Paper›PMID 29854086›Full record

ReviewOxidative medicine and cellular longevity2018

Regulated Cell Death as a Therapeutic Target for Novel Antifungal Peptides and Biologics.

Michael R Yeaman, Sabrina Büttner, Karin Thevissen

Abstract readReview
In one paragraph

Review in Oxidative medicine and cellular longevity, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Future microbiology · 2024
    Article
  5. Article
  6. Newly Discovered Antimicrobial Peptide ScyampcinAntimicrobial agents and chemotherapy · 2023
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Cuminal InhibitsMicroorganisms · 2020
    Article
  12. Article
  13. Unifying structural signature of eukaryotic α-helical host defense peptides.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Michael R YeamanDivision of Molecular Medicine, Los Angeles County Harbor-UCLA Medical Center, Torrance, CA 90502, USA.ORCID 0000-0002-9468-5252
Sabrina BüttnerDepartment of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, Stockholm, Sweden.
Karin ThevissenCentre of Microbial and Plant Genetics (CMPG), KU Leuven, Leuven, Belgium.ORCID 0000-0003-0275-9072

Funding

Systems Immunolobiology of Antibiotic-Persistent MRSA InfectionU01AI124319 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI YEAMAN, MICHAEL R · 2016 to 2020
$10.1M
Austrian Science Fund FWF P 27183NIAID NIH HHS U01 AI124319
6 · The paper itself

Abstract

The rise of microbial pathogens refractory to conventional antibiotics represents one of the most urgent and global public health concerns for the 21st century. Emergence of

Indexed as

Antifungal AgentsBiological ProductsCell DeathHumansAntifungal AgentsBiological Products

Identifiers

PMID29854086
PMCPMC5944218

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.